Semimechanistically Based Modeling of Pembrolizumab Time-Varying Clearance Using 4 Longitudinal Covariates in Patients With Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Semimechanistically Based Modeling of Pembrolizumab Time-Varying Clearance Using 4 Longitudinal Covariates in Patients With Non–Small Cell Lung Cancer

Published:2019-01 Issue:1 Volume:108 Page:692-700
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Li Hongshan,Sun Yaning,Yu Jingyu,Liu Chao,Liu Jiang,Wang Yaning

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference29 articles.

1. Breakthrough of the year 2013. Cancer immunotherapy;Couzin-Frankel;Science,2013

2. Immune checkpoint inhibitors for patients with advanced non-small-cell lung cancer: a systematic review;Ellis;Clin Lung Cancer,2017

3. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies;Gravelle;Oncotarget,2017

4. Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy;Xue;J Hematol Oncol,2017

5. A review of the PD-1/PD-L1 checkpoint in bladder cancer: from mediator of immune escape to target for treatment;Zhou;Urol Oncol,2017

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients;British Journal of Clinical Pharmacology;2023-12-29

2. Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors;Clinical Cancer Research;2023-12-13

3. Time-Dependent Pharmacokinetics of Immune Checkpoint Inhibitors and their Implications and Considerations for Exposure–Response Analysis;Current Pharmacology Reports;2023-11-03

4. Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients;Clinical Pharmacokinetics;2023-07-13

5. Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics;BMC Cancer;2023-05-19